CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood's Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock and raised the price target to $80 from $65. The price target adjustment follows the stock's strong performance, depicted by 41% year-to-date gain.
Likewise, the research firm has echoed CRISPR Therapeutics' second-quarter results, which showed a 114% quarter-over-quarter increase in CASGEVY sales to $30 million. The significant growth came from the treatment being infused in 16 patients, double the eight infusions done in the first quarter.
The number of infusions has been increasing steadily, from four patients in the fourth quarter of 2024 to one patient in the third quarter. Revenues have also increased steadily from $2 million in the third quarter of last year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.